HCPCS Level II code M0075 designates cellular therapy services, covering the handling, processing, or provision of cellular products used in therapeutic treatments. This code is relevant nationally as cellular therapies expand across oncology, immunology, and regenerative medicine, driving demand for standardized billing and payer coverage policies. Clear coding for cellular therapy affects facility billing workflows, reimbursement consistency, and access to advanced treatments.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common billing modifiers, and clinical context for when M0075 is used. The publication summarizes typical sites of service and service line implications, highlights coding relationships, and outlines where input was not available.

What readers will learn: benchmarks and typical billing contexts for cellular therapy claims using M0075, payer coverage patterns and policy considerations, and practical clinical settings where the code applies. Data not provided in the input is identified as such. The content is national in scope and intended for billing managers, revenue cycle professionals, and policy analysts tracking advanced therapy reimbursement.